Drugs / Drospirenone/Ethinyl Estradiol
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01182194 | Jun → Aug 2006 | — | Teva Pharmaceuticals USA | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Drospirenone/Ethinyl Estradiol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01182194 ↗ |
| Known as | YAZ | “This study was designed to compare the relative bioavailability (rate and extent of absorption) of 3 mg/0.02 mg Drospirenone/Ethinyl Estradiol Tablets with that of YAZ® Tablets...” NCT01182194 ↗ |
| Route | Oral | “single, oral dose” NCT01182194 ↗ |